Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

Inclusion Criteria: * Signed informed consent in a language understandable to the subject prior to any study-mandated procedure. * Body mass index of 18.0 to 28.0 kg/m\^2 (inclusive) at the screening. * Ability to communicate well with the investigator, in a language understandable to the subject, and to understand and comply with the requirements of the study. * No clinically relevant findings on the physical examination at screening. * Systolic blood pressure 100 to 145 mmHg, diastolic blood pressure 50 to 90 mmHg, and pulse rate 55 to 90 bpm (inclusive), measured on the same arm, after 5 min in the supine position at screening and on admission. * 12-lead ECG without clinically relevant abnormalities, measured after 5 min in the supine position at Screening and on admission. * No clinically relevant findings in clinical laboratory tests (hematology, clinical chemistry, and urinalysis) at screening and on admission. * Negative results from urine drug screen and breath alcohol tests at screening and on admission. * Subjects must be of Caucasian or Japanese ethnicity. Exclusion Criteria: * Previous exposure to cenerimod. * Known hypersensitivity or allergy to natural rubber latex, to or any of the excipients. * History of major medical or surgical disorders which are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed). * Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the evaluation. * Clinically relevant history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions. * Lymphopenia (less than 1.0 x 10\^9 cells/L) at screening and on admission. * Familial history of sick-sinus syndrome. * Any cardiac condition or illness (including Electrocardiogram (ECG) abnormalities with a potential to increase the cardiac risk. * Familial history of sick-sinus syndrome. * Any recent immunosuppressive treatment. * History or clinical evidence of alcoholism or drug abuse. * Excessive caffeine consumption, defined as 800 mg or more per day at screening. * Nicotine consumption within 3 months prior to screening and inability to refrain from nicotine consumption. * Previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals). * Viral, fungal, bacterial or protozoal infection and / or serology. * Legal incapacity or limited legal capacity at screening.